Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
Previous Symbol
CUSIPN/A
Phone646-844-1164
Debt
Debt-to-Equity RatioN/A
Current Ratio6.82
Quick Ratio6.82
Price-To-Earnings
Trailing P/E Ratio-4.70
Forward P/E Ratio-3.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.45 million
Price / Sales28.66
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.79 per share
Price / Book2.26
Profitability
EPS (Most Recent Fiscal Year)($0.86)
Net Income$-12,720,000.00
Net Margins-519.68%
Return on Equity-55.96%
Return on Assets-31.46%
Miscellaneous
Employees13
Outstanding Shares17,380,000
Market Cap$70.21 million
OptionableOptionable
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
How were Oramed Pharmaceuticals' earnings last quarter?
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Wednesday, November, 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.10. The biotechnology company earned $0.62 million during the quarter. Oramed Pharmaceuticals had a negative return on equity of 55.96% and a negative net margin of 519.68%. View Oramed Pharmaceuticals' Earnings History.
When is Oramed Pharmaceuticals' next earnings date?
What price target have analysts set for ORMP?
2 brokers have issued 12-month target prices for Oramed Pharmaceuticals' stock. Their predictions range from $20.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $22.50 in the next twelve months. This suggests a possible upside of 456.9% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.
What is the consensus analysts' recommendation for Oramed Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.
Has Oramed Pharmaceuticals been receiving favorable news coverage?
News articles about ORMP stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news impact score of 1.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include MannKind (MNKD), Geron (GERN), Adamas Pharmaceuticals (ADMS), Savara (SVRA), Kadmon (KDMN), Athersys (ATHX), Verrica Pharmaceuticals (VRCA), Merus (MRUS), Magenta Therapeutics (MGTA), Syros Pharmaceuticals (SYRS), Tocagen (TOCA), BioDelivery Sciences International (BDSI), AVEO Pharmaceuticals (AVEO), Affimed (AFMD) and Catalyst Pharmaceuticals (CPRX).
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Mr. Nadav Kidron Esq., Pres, CEO & Exec. Director (Age 44)
- Dr. Miriam Kidron Ph.D., Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 78)
- Ms. Hilla Eisenberg CPA, CFO, Treasurer, Sec. and Principal Financial & Accounting Officer (Age 34)
- Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board
- Dr. Ronald Law, Chief Strategy Officer (Age 65)
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $4.04.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $70.21 million and generates $2.45 million in revenue each year. The biotechnology company earns $-12,720,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Oramed Pharmaceuticals employs 13 workers across the globe.
What is Oramed Pharmaceuticals' official website?
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is 142 W. 57TH STREET 11TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 646-844-1164 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
